Cargando…
Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology
Tofacitinib, an oral Janus kinase inhibitor (Jakinib), is an emerging treatment modality whose well-established efficacy in systemic inflammatory diseases is now being actively explored for cutaneous disorders (arising due to the patient's dysimmune responses) that are not responding to and/or...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743407/ https://www.ncbi.nlm.nih.gov/pubmed/31544068 http://dx.doi.org/10.4103/idoj.IDOJ_474_18 |